Panelists discuss how recent updates from the phase 3 IsKia trial demonstrate that isatuximab combined with carfilzomib, lenalidomide, and dexamethasone improves minimal residual disease negativity ...

The authors concluded that even mild 18 F-FDG uptake may indicate the presence of lymphoma in areas of the brain where the blood-brain barrier is intact. They recommended clinicians be suspicious of ...

Panelists discuss how the PERSEUS trial’s subgroup analysis reinforced that sustained minimal residual disease negativity predicts better long-term outcomes and demonstrated the potential for ...

Jason Westin, from the MD Anderson Cancer Center (Houston, TX, USA), presented the primary results of the randomised, ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...